James D Brooks

List of Publications by Citations

160 papers	5,345 citations	35 h-index	69 g-index
170 ext. papers	6,254 ext. citations	4.9 avg, IF	5.5 L-index

#	Paper	IF	Citations
160	Gene expression profiling identifies clinically relevant subtypes of prostate cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 811-6	11.5	1047
159	Differential DNA methylation with age displays both common and dynamic features across human tissues that are influenced by CpG landscape. *Genome Biology*, **2013**, 14, R102	18.3	239
158	PLASMA SELENIUM LEVEL BEFORE DIAGNOSIS AND THE RISK OF PROSTATE CANCER DEVELOPMENT. *Journal of Urology*, **2001**, 166, 2034-2038	2.5	182
157	GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. *American Journal of Pathology*, **2001**, 159, 1815-26	5.8	180
156	DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. *Genome Research*, **2011**, 21, 1017-27	9.7	179
155	Gene expression profiling predicts survival in conventional renal cell carcinoma. *PLoS Medicine*, **2006**, 3, e13	11.6	154
154	Transcriptional programs activated by exposure of human prostate cancer cells to androgen. *Genome Biology*, **2002**, 3, RESEARCH0032	18.3	140
153	Diagnosis of prostate cancer by desorption electrospray ionization mass spectrometric imaging of small metabolites and lipids. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, 3334-3339	11.5	118
152	Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas. *Prostate*, **1995**, 26, 35-9	4.2	110
151	Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays. *Prostate*, **2004**, 59, 243-51	4.2	109
150	Prostate Magnetic Resonance Imaging Interpretation Varies Substantially Across Radiologists. *European Urology Focus*, **2019**, 5, 592-599	5.1	107
149	Increased risk of cancer in infertile men: analysis of U.S. claims data. *Journal of Urology*, **2015**, 193, 1596-601	2.5	105
148	Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. *Journal of Urology*, **2016**, 195, 313-20	2.5	93
147	Novel pathways associated with bypassing cellular senescence in human prostate epithelial cells. *Journal of Biological Chemistry*, **2002**, 277, 14877-83	5.4	92
146	Diverse effects of methylseleninic acid on the transcriptional program of human prostate cancer cells. *Molecular Biology of the Cell*, **2004**, 15, 506-19	3.5	91
145	Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy. *Journal of Clinical Oncology*, **2005**, 23, 6157-62	2.2	82
144	Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era. *International Journal of Cancer*, **2014**, 134, 2245-52	7.5	81

143	Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized: Analysis of the Relative Prognostic Strength of Individual Architectural Patterns in 1275 Patients From the Canary Retrospective Cohort. *American Journal of Surgical Pathology*, **2016**, 40, 1439-1456	6.7	79
142	Translational genomics: the challenge of developing cancer biomarkers. *Genome Research*, **2012**, 22, 183-7	9.7	70
141	Utilization of renal mass biopsy in patients with renal cell carcinoma. *Urology*, **2014**, 83, 774-9	1.6	68
140	Resveratrol-induced gene expression profiles in human prostate cancer cells. *Cancer Epidemiology Biomarkers and Prevention*, **2005**, 14, 596-604	4	66
139	Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH. *Modern Pathology*, **2016**, 29, 904-14	9.8	61
138	Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines. *Prostate*, **2005**, 63, 187-97	4.2	60
137	MALE PELVIC ANATOMY RECONSTRUCTED FROM THE VISIBLE HUMAN DATA SET. *Journal of Urology*, **1998**, 159, 868-872	2.5	54
136	PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer. *European Urology Focus*, **2016**, 2, 180-188	5.1	52
135	Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository. *Urology*, **2010**, 75, 407-13	1.6	48
134	A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer. *Prostate*, **2015**, 75, 1206-15	4.2	47
133	Simultaneous transrectal ultrasound and photoacoustic human prostate imaging. *Science Translational Medicine*, **2019**, 11,	17.5	45
132	NUSAP1 promotes invasion and metastasis of prostate cancer. *Oncotarget*, **2017**, 8, 29935-29950	3.3	41
131	Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary-Early Detection Research Network Active Surveillance Biopsy Risk Calculator. *European Urology*, **2015**, 68, 1083-8	19.2	39
130	Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 2032-2042	11.5	38
129	Distinctive gene expression of prostatic stromal cells cultured from diseased versus normal tissues. *Journal of Cellular Physiology*, **2007**, 210, 111-21	7	38
128	Increased expression of GCNT1 is associated with altered O-glycosylation of PSA, PAP, and MUC1 in human prostate cancers. *Prostate*, **2014**, 74, 1059-67	4.2	37
127	Temporal changes in gene expression induced by sulforaphane in human prostate cancer cells. *Prostate*, **2009**, 69, 181-90	4.2	36
126	DNA methylation profiling reveals novel diagnostic biomarkers in renal cell carcinoma. *BMC Medicine*, **2014**, 12, 235	11.4	35

125	Differential gene-expression patterns in genital fibroblasts of normal males and 46,XY females with androgen insensitivity syndrome: evidence for early programming involving the androgen receptor. *Genome Biology*, **2003**, 4, R37	18.3	35
124	Cell-line and tissue-specific signatures of androgen receptor-coregulator transcription. *Journal of Molecular Medicine*, **2006**, 84, 919-31	5.5	34
123	Ferroptosis Inducers Are a Novel Therapeutic Approach for Advanced Prostate Cancer. *Cancer Research*, **2021**, 81, 1583-1594	10.1	34
122	Lower body mass index is associated with a higher prostate cancer detection rate and less favorable pathological features in a biopsy population. *Journal of Urology*, **2004**, 171, 2199-202	2.5	33
121	GSTP1 Loss results in accumulation of oxidative DNA base damage and promotes prostate cancer cell survival following exposure to protracted oxidative stress. *Prostate*, **2016**, 76, 199-206	4.2	33
120	Genome-wide DNA methylation measurements in prostate tissues uncovers novel prostate cancer diagnostic biomarkers and transcription factor binding patterns. *BMC Cancer*, **2017**, 17, 273	4.8	32
119	NUSAP1 expression is upregulated by loss of RB1 in prostate cancer cells. *Prostate*, **2015**, 75, 517-26	4.2	31
118	Intrinsic androgen-dependent gene expression patterns revealed by comparison of genital fibroblasts from normal males and individuals with complete and partial androgen insensitivity syndrome. *BMC Genomics*, **2007**, 8, 376	4.5	29
117	Modest induction of phase 2 enzyme activity in the F-344 rat prostate. *BMC Cancer*, **2006**, 6, 62	4.8	29
116	Anatomy of the rectourethralis muscle. *European Urology*, **2002**, 41, 94-100	10.2	29
115	The Role of DNA Methylation in Renal Cell Carcinoma. *Molecular Diagnosis and Therapy*, **2018**, 22, 431-442	4.5	29
114	Molecular genetics and chromosomal alterations in prostate cancer. *Cancer*, **1995**, 75, 2004-2012	6.4	27
113	Architecture and Implementation of a Clinical Research Data Warehouse for Prostate Cancer. *EGEMS (Washington, DC)*, **2018**, 6, 13	2.2	27
112	17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort. *Journal of Clinical Oncology*, **2020**, 38, 1549-1557	2.2	26
111	Prostate cancer risk profiles of Asian-American men: disentangling the effects of immigration status and race/ethnicity. *Journal of Urology*, **2014**, 191, 952-6	2.5	26
110	The radiogenomic risk score stratifies outcomes in a renal cell cancer phase 2 clinical trial. *European Radiology*, **2016**, 26, 2798-807	8	25
109	Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients. *PLoS ONE*, **2015**, 10, e0132343	3.7	25
108	Apolipoprotein D (APOD) is a putative biomarker of androgen receptor function in androgen insensitivity syndrome. *Journal of Molecular Medicine*, **2009**, 87, 623-32	5.5	25

107	Multi-lectin Affinity Chromatography and Quantitative Proteomic Analysis Reveal Differential Glycoform Levels between Prostate Cancer and Benign Prostatic Hyperplasia Sera. *Scientific Reports*, **2018**, 8, 6509	4.9	23
106	Microarray Data Mining for Potential Selenium Targets in Chemoprevention of Prostate Cancer. *Cancer Genomics and Proteomics*, **2005**, 2, 97-114	3.3	23
105	Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes. *European Urology*, **2018**, 74, 211-217	10.2	22
104	S100A10 Is a Critical Mediator of GAS6/AXL-Induced Angiogenesis in Renal Cell Carcinoma. *Cancer Research*, **2019**, 79, 5758-5768	10.1	21
103	hCAP-D3 expression marks a prostate cancer subtype with favorable clinical behavior and androgen signaling signature. *American Journal of Surgical Pathology*, **2008**, 32, 205-9	6.7	21
102	Microarray analysis in prostate cancer research. *Current Opinion in Urology*, **2002**, 12, 395-9	2.8	21
101	African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study. *Journal of Urology*, **2020**, 203, 727-733	2.5	20
100	Weakly supervised natural language processing for assessing patient-centered outcome following prostate cancer treatment. *JAMIA Open*, **2019**, 2, 150-159	2.9	19
99	MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study. *PLoS ONE*, **2016**, 11, e0165236	3.7	19
98	ProsRegNet: A deep learning framework for registration of MRI and histopathology images of the prostate. *Medical Image Analysis*, **2021**, 68, 101919	15.4	19
97	The mA RNA demethylase FTO is a HIF-independent synthetic lethal partner with the VHL tumor suppressor. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 21441-21449	11.5	18
96	Overall Survival in Patients with Localized Prostate Cancer in the US Veterans Health Administration: Is PIVOT Generalizable?. *European Urology*, **2016**, 70, 227-30	10.2	17
95	Contemporary Use of Partial Nephrectomy: Are Older Patients With Impaired Kidney Function Being Left Behind?. *Urology*, **2017**, 100, 65-71	1.6	17
94	Selenomethionine induced transcriptional programs in human prostate cancer cells. *Journal of Urology*, **2007**, 177, 743-50	2.5	17
93	Loss of Expression of AZGP1 Is Associated With Worse Clinical Outcomes in a Multi-Institutional Radical Prostatectomy Cohort. *Prostate*, **2016**, 76, 1409-19	4.2	17
92	Novel lincRNA SLINKY is a prognostic biomarker in kidney cancer. *Oncotarget*, **2017**, 8, 18657-18669	3.3	16
91	Methods for registration of magnetic resonance images of ex vivo prostate specimens with histology. *Journal of Magnetic Resonance Imaging*, **2012**, 36, 206-12	5.6	15
90	A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue Microarray. *Advances in Anatomic Pathology*, **2013**, 20, 39-44	5.1	15

89	Anatomy of the Lower Urinary Tract and Male Genitalia **2012**, 33-70.e2		14
88	Identification of diagnostic metabolic signatures in clear cell renal cell carcinoma using mass spectrometry imaging. *International Journal of Cancer*, **2020**, 147, 256-265	7.5	14
87	Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability. *JAMA Oncology*, **2020**, 6, e203187	13.4	14
86	Alteration of gene expression signatures of cortical differentiation and wound response in lethal clear cell renal cell carcinomas. *PLoS ONE*, **2009**, 4, e6039	3.7	13
85	Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancer. *Oncotarget* , **2018**, 9, 6550-6561	3.3	13
84	Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS). *Prostate Cancer and Prostatic Diseases*, **2019**, 22, 438-445	6.2	12
83	Improved detection of prostate cancer using a magneto-nanosensor assay for serum circulating autoantibodies. *PLoS ONE*, **2019**, 14, e0221051	3.7	12
82	Gene expression changes induced by unilateral ureteral obstruction in mice. *Journal of Urology*, **2012**, 188, 1033-41	2.5	12
81	PSA Testing Use and Prostate Cancer Diagnostic Stage After the 2012 U.S. Preventive Services Task Force Guideline Changes. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2019**, 17, 795-803	7.2	12
80	Registration of presurgical MRI and histopathology images from radical prostatectomy via RAPSODI. *Medical Physics*, **2020**, 47, 4177-4188	4.4	11
79	The feasibility of assessing branched-chain amino acid metabolism in cellular models of prostate cancer with hyperpolarized [1-(13)C]-ketoisocaproate. *Magnetic Resonance Imaging*, **2014**, 32, 791-5	3.3	11
78	Role of cytologic criteria in the histologic diagnosis of Gleason grade 1 prostatic adenocarcinoma. *Human Pathology*, **2001**, 32, 441-6	3.7	11
77	3D Registration of pre-surgical prostate MRI and histopathology images via super-resolution volume reconstruction. *Medical Image Analysis*, **2021**, 69, 101957	15.4	11
76	Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study. *Journal of Urology*, **2017**, 197, 1026-1033	2.5	10
75	A Magnetic Bead-Based Sensor for the Quantification of Multiple Prostate Cancer Biomarkers. *PLoS ONE*, **2015**, 10, e0139484	3.7	10
74	Genomic analysis of benign prostatic hyperplasia implicates cellular re-landscaping in disease pathogenesis. *JCI Insight*, **2019**, 5,	9.9	10
73	Leveraging Digital Data to Inform and Improve Quality Cancer Care. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 816-822	4	9
72	Mining Electronic Health Records to Extract Patient-Centered Outcomes Following Prostate Cancer Treatment **2017**, 2017, 876-882	0.7	9

71	Automated detection of aggressive and indolent prostate cancer on magnetic resonance imaging. *Medical Physics*, **2021**, 48, 2960-2972	4.4	9
70	The Research Implications of Prostate Specific Antigen Registry Errors: Data from the Veterans Health Administration. *Journal of Urology*, **2018**, 200, 541-548	2.5	8
69	Accuracy of Prostate-Specific Antigen Values in Prostate Cancer Registries. *Journal of Clinical Oncology*, **2016**, 34, 3586-3587	2.2	8
68	Distribution of global health measures from routinely collected PROMIS surveys in patients with breast cancer or prostate cancer. *Cancer*, **2019**, 125, 943-951	6.4	8
67	Association between patient-initiated emails and overall 2-year survival in cancer patients undergoing chemotherapy: Evidence from the real-world setting. *Cancer Medicine*, **2020**, 9, 8552-8561	4.8	7
66	The CPC Risk Calculator: A New App to Predict Prostate-specific Antigen Recurrence During Follow-up After Radical Prostatectomy. *European Urology Focus*, **2018**, 4, 360-368	5.1	7
65	Early detection of unilateral ureteral obstruction by desorption electrospray ionization mass spectrometry. *Scientific Reports*, **2019**, 9, 11007	4.9	7
64	Silencing of pi-class glutathione S-transferase in MDA PCa 2a and MDA PCa 2b cells. *Prostate*, **2002**, 51, 225-30	4.2	7
63	MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer. *Scientific Reports*, **2021**, 11, 13305	4.9	7
62	Elevated urinary lipocalin-2, interleukin-6 and monocyte chemoattractant protein-1 levels in children with congenital ureteropelvic junction obstruction. *Journal of Pediatric Urology*, **2019**, 15, 44.e1-44.e7	1.5	7
61	Identification of transcripts associated with renal damage due to ureteral obstruction as candidate urinary biomarkers. *American Journal of Physiology - Renal Physiology*, **2018**, 315, F16-F26	4.3	6
60	The Impact of Tumor Volume on Outcomes after Radical Prostatectomy: Implications for Prostate Cancer Screening. *The Open Prostate Cancer Journal*, **2008**, 1, 1-8		6
59	Identification of potential prostate cancer preventive agents through induction of quinone reductase in vitro. *Cancer Epidemiology Biomarkers and Prevention*, **2002**, 11, 868-75	4	6
58	miR-22 Regulates Invasion, Gene Expression and Predicts Overall Survival in Patients with Clear Cell Renal Cell Carcinoma. *Kidney Cancer*, **2019**, 3, 119-132	0.6	5
57	Comparison of orthogonal NLP methods for clinical phenotyping and assessment of bone scan utilization among prostate cancer patients. *Journal of Biomedical Informatics*, **2019**, 94, 103184	10.2	5
56	Identifying Cases of Metastatic Prostate Cancer Using Machine Learning on Electronic Health Records **2018**, 2018, 1498-1504	0.7	5
55	Extracting Patient-Centered Outcomes from Clinical Notes in Electronic Health Records: Assessment of Urinary Incontinence After Radical Prostatectomy. *EGEMS (Washington, DC)*, **2019**, 7, 43	2.2	5
54	Clinical Trial Outcomes in Urology: Assessing Early Discontinuation, Results Reporting and Publication in ClinicalTrials.Gov Registrations 2007-2019. *Journal of Urology*, **2021**, 205, 1159-1168	2.5	5

53	Performance of multiparametric MRI appears better when measured in patients who undergo radical prostatectomy. *Research and Reports in Urology*, **2018**, 10, 233-235	1.3	5
52	A natural language processing algorithm to measure quality prostate cancer care.. *Journal of Clinical Oncology*, **2017**, 35, 232-232	2.2	4
51	Development of a DNA Methylation-Based Diagnostic Signature to Distinguish Benign Oncocytoma From Renal Cell Carcinoma. *JCO Precision Oncology*, **2020**, 4,	3.6	4
50	Utilization of Prostate Cancer Quality Metrics for Research and Quality Improvement: A Structured Review. *Joint Commission Journal on Quality and Patient Safety*, **2019**, 45, 217-226	1.4	4
49	Early-Life Cardiorespiratory Fitness and Long-term Risk of Prostate Cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 2187-2194	4	3
48	Clinical Documentation to Predict Factors Associated with Urinary Incontinence Following Prostatectomy for Prostate Cancer. *Research and Reports in Urology*, **2020**, 12, 7-14	1.3	3
47	Comparative rates of upstaging and upgrading in Caucasian and Korean prostate cancer patients eligible for active surveillance. *PLoS ONE*, **2017**, 12, e0186026	3.7	3
46	Temporal Trends in Clinical and Pathological Characteristics for Men Undergoing Radical Prostatectomy Between 1995 and 2013 at Rigshospitalet, Copenhagen, Denmark, and Stanford University Hospital, United States. *Clinical Genitourinary Cancer*, **2017**,	3.3	3
45	SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer.. *Cell Reports Medicine*, **2022**, 3, 100502	18	3
44	Framework for the co-registration of MRI and histology images in prostate cancer patients with radical prostatectomy **2019**,		3
43	Detection of prostate cancer and determination of its significance using explainable artificial intelligence.. *Journal of Clinical Oncology*, **2020**, 38, 5555-5555	2.2	3
42	Selective identification and localization of indolent and aggressive prostate cancers via CorrSigNIA: an MRI-pathology correlation and deep learning framework. *Medical Image Analysis*, **2021**, 75, 102288	15.4	3
41	Machine Learning Approaches for Extracting Stage from Pathology Reports in Prostate Cancer. *Studies in Health Technology and Informatics*, **2019**, 264, 1522-1523	0.5	3
40	Life expectancy estimates for patients diagnosed with prostate cancer in the Veterans Health Administration. *Urologic Oncology: Seminars and Original Investigations*, **2020**, 38, 734.e1-734.e10	2.8	3
39	Predictive value of AZGP1 following radical prostatectomy for prostate cancer: a cohort study and meta-analysis. *Journal of Clinical Pathology*, **2019**, 72, 696-704	3.9	2
38	Applying the PRECISION approach in biopsy naïve and previously negative prostate biopsy patients. *Urologic Oncology: Seminars and Original Investigations*, **2019**, 37, 530.e19-530.e24	2.8	2
37	Is it possible to automatically assess pretreatment digital rectal examination documentation using natural language processing? A single-centre retrospective study. *BMJ Open*, **2019**, 9, e027182	3	2
36	Application of genomic technologies to human prostate cancer. *OMICS A Journal of Integrative Biology*, **2006**, 10, 261-75	3.8	2

35	Protein signatures to distinguish aggressive from indolent prostate cancer.. *Prostate*, **2022**,	4.2	2
34	An Automated Feature Engineering for Digital Rectal Examination Documentation using Natural Language Processing **2018**, 2018, 288-294	0.7	2
33	The Urine Albumin-to-Creatinine Ratio and Kidney Function after Nephrectomy. *Journal of Urology*, **2020**, 204, 231-238	2.5	2
32	Oncogene-mediated metabolic gene signature predicts breast cancer outcome. *Npj Breast Cancer*, **2021**, 7, 141	7.8	2
31	protects against renal injury by decreasing the level of reactive oxygen species in female mice. *American Journal of Physiology - Renal Physiology*, **2020**, 319, F876-F884	4.3	2
30	Phenotyping severity of patient-centered outcomes using clinical notes: A prostate cancer use case. *Learning Health Systems*, **2020**, 4, e10237	3	2
29	Diverse patient trajectories during cytotoxic chemotherapy: Capturing longitudinal patient-reported outcomes. *Cancer Medicine*, **2021**, 10, 5783-5793	4.8	2
28	Real-world Evidence to Estimate Prostate Cancer Costs for First-line Treatment or Active Surveillance. *European Urology Open Science*, **2021**, 23, 20-29	0.9	2
27	Weakly Supervised Registration of Prostate MRI and Histopathology Images. *Lecture Notes in Computer Science*, **2021**, 98-107	0.9	2
26	Imaging of Methionine Aminopeptidase II for Prostate Cancer Risk Stratification. *Cancer Research*, **2021**, 81, 2510-2521	10.1	2
25	Assessment of a Clinical Trial-Derived Survival Model in Patients With Metastatic Castration-Resistant Prostate Cancer. *JAMA Network Open*, **2021**, 4, e2031730	10.4	2
24	Determination of biologic and prognostic feature scores from whole slide histology images using deep learning.. *Journal of Clinical Oncology*, **2020**, 38, e17527-e17527	2.2	1
23	Consumption of cruciferous vegetables and the risk of bladder cancer in a prospective US cohort: data from the NIH-AARP diet and health study. *American Journal of Clinical and Experimental Urology*, **2021**, 9, 229-238	1.6	1
22	Machine Learning Applied to Electronic Health Records: Identification of Chemotherapy Patients at High Risk for Preventable Emergency Department Visits and Hospital Admissions. *JCO Clinical Cancer Informatics*, **2021**, 5, 1106-1126	5.2	1
21	AZGP1 Protein Expression in Hormone-Naïve Advanced Prostate Cancer Treated with Primary Androgen Deprivation Therapy. *Diagnostics*, **2020**, 10,	3.8	1
20	Multiregion Quantification of Extracellular Signal-regulated Kinase Activity in Renal Cell Carcinoma. *European Urology Oncology*, **2020**, 3, 360-364	6.7	1
19	Laboratory-wide association study of survival with prostate cancer. *Cancer*, **2021**, 127, 1102-1113	6.4	1
18	Re: Brandon A. Mahal, David D. Yang, Natalie Q. Wang, et al. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol 2018;74:146-54. *European Urology*, **2018**, 74, e110-e111	10.2	1

17	Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer. *Cancer*, **2021**,	6.4	1
16	Prevalence of Postprostatectomy Incontinence Requiring Anti-incontinence Surgery After Radical Prostatectomy for Prostate Cancer: A Retrospective Population-Based Analysis. *International Neurourology Journal*, **2021**, 25, 263-270	2.6	1
15	Sialylated glycoproteins as biomarkers and drivers of progression in prostate cancer. *Carbohydrate Research*, **2022**, 108598	2.9	1
14	Using an Automated Electronic Health Record Score To Estimate Life Expectancy In Men Diagnosed With Prostate Cancer In The Veterans Health Administration. *Urology*, **2021**, 155, 70-76	1.6	0
13	Reply: To PMID 24529583. *Urology*, **2014**, 83, 779-80	1.6	
12	Editorial Comment. *Journal of Urology*, **2020**, 203, 350	2.5	
11	PIVOT and the challenges of localized prostate cancer care. *Translational Andrology and Urology*, **2012**, 1, 141-3	2.3	
10	Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results From the Canary PASS Cohort. *Journal of Urology*, **2021**, 101097JU0000000000002354	2.5	
9	Editorial Comment on Considerations in the Analysis of Clinical Trial Failure. I.. *Journal of Urology*, **2022**, 101097JU0000000000002428	2.5	
8	Survival trends in patients diagnosed with metastatic prostate cancer: A nationwide analysis.. *Journal of Clinical Oncology*, **2017**, 35, 171-171	2.2	
7	The use of five-alpha reductase inhibitors and their association with reclassification and pathologic outcomes in the Canary Prostate Active Surveillance Study (PASS).. *Journal of Clinical Oncology*, **2017**, 35, 22-22	2.2	
6	Sudden PSA rise to ⩾10 ng/ml and prostate cancer diagnosis in the United States: A population-based study. *Prostate*, **2020**, 80, 1438-1443	4.2	
5	Identification of patients at high risk for preventable emergency department visits and inpatient admissions after starting chemotherapy: Machine learning applied to comprehensive electronic health record data.. *Journal of Clinical Oncology*, **2021**, 39, 1511-1511	2.2	
4	Effect of Diagnostic Biopsy Practice Location on Grade/Volume Reclassification in Active Surveillance for Prostate Cancer: A Multicenter Analysis from the Canary PASS Cohort. *Urology Practice*, **2021**, 8, 576-582	0.8	
3	AUTHOR REPLY. *Urology*, **2021**, 155, 76	1.6	
2	Clinical laboratory tests associated with survival in patients with metastatic renal cell carcinoma: A Laboratory Wide Association Study (LWAS). *Urologic Oncology: Seminars and Original Investigations*, **2022**, 40, 12.e23-12.e30	2.8	
1	Cost-Effectiveness Analysis and Microsimulation of Serial Multiparametric Magnetic Resonance Imaging in Active Surveillance of Localized Prostate Cancer.. *Journal of Urology*, **2022**, 101097JU0000000000002490	2.5	